The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Outcomes of allogeneic stem cell transplantation in elderly patients
Yngvar Floisand, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses outcomes associated with allogeneic stem cell transplantation in elderly patients (65 years or above) with acute myeloid leukemia or myelodysplastic syndrome, the findings of which support the use of this treatment approach in elderly patients. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
